Enozertinib (ORIC-114)
NSCLC (EGFR exon 20 & PACC mutations)
Phase 1b/2Active
Key Facts
Indication
NSCLC (EGFR exon 20 & PACC mutations)
Phase
Phase 1b/2
Status
Active
Company
About ORIC Pharmaceuticals
ORIC Pharmaceuticals is a clinical-stage biotech with a mission to overcome therapeutic resistance in cancer, a primary cause of treatment failure. The company has successfully raised over $900 million, advanced four programs into clinical trials, and is progressing key assets like ORIC-114 and rinzimetostat (ORIC-944) in late-phase 1b/2 studies. Its strategy centers on a proprietary resistance platform to develop combination therapies that extend the efficacy of standard-of-care treatments, positioning it as a potential partner of choice in the oncology landscape.
View full company profile